Semaglutide was originally developed for type 2 diabetes, where it produces HbA1c reductions of 1.52.0 percentage points
Participants randomized to the 4 mg dose with a 2 mg starting dose had significantly fewer GI adverse events than those started directly at 4 mg
"Additional monitoring of kidney function may be needed when starting, or increasing, doses of GLP-1 medications." Kidney Care UK The frequency of follow-up tests should match the patients CKD stage and individual risks
Results Controls The detailed sequential description of the figures is given in the legends
When you put all of that together, its easy to see why a multipronged approach to easing symptoms would be a more successful route
Less frequent but more serious risks include pancreatitis, gallbladder issues, and in rare cases, thyroid tumors